# Study Published in Pediatrics Finds Infrequent Cannabis Use Can Impact Adolescent … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/study-published-in-pediatrics-finds-infrequent-cannabis-use-can-impact-adolescent/ > **Published:** 2026-07-25T07:19:40-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:02:50-04:00 > **Clinical Summary:** New research on adolescent cannabis use shows neurobehavioral effects even with infrequent use. Clinical guidance for screening and counseling teens. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchPediatricsMental HealthSafetyTHCNeurologyAnxiety Why This Matters Clinicians caring for adolescents need this evidence to counsel patients and families that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) frequency does not need to be heavy to cause harm, as even monthly use may impair neurodevelopment during a critical brain maturation period. This finding supports stronger clinical screening and prevention messaging, since adolescents and parents often underestimate risks associated with occasional use compared to daily consumption. Early identification of even infrequent [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) allows clinicians to intervene before patterns escalate and before documented developmental impacts accumulate. Clinical Summary A longitudinal study published in Pediatrics by Columbia and Weill Cornell Medicine researchers found that even infrequent [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in adolescents, as little as once monthly, is associated with negative impacts on brain development and [cognitive function](https://cedclinic.com/reverse-cholesterol-transport-function-cannabis-users/) during a critical developmental period. The study strengthens evidence that the adolescent brain’s ongoing maturation through the early twenties makes it particularly vulnerable to cannabis’s effects on attention, memory, and executive function, even at low use frequencies. These findings are clinically relevant because many adolescents and their parents underestimate the risks of occasional cannabis use, viewing it as safer than more frequent consumption. Clinicians should be aware that the traditional harm-reduction messaging focusing on reducing frequency may not adequately protect adolescent neurodevelopment, as any regular use carries measurable risks. Pediatricians and mental health providers should counsel patients and families that current evidence does not support a “safe” threshold for [adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) and emphasize complete abstinence during the teenage years as the evidence-based recommendation. Dr. Caplan’s Take “This peer-reviewed finding from Columbia and Weill Cornell is important because it challenges the assumption that infrequent use is risk-free in developing brains, but we need to be careful about extrapolating causation from observational data and understand what specific neurodevelopmental impacts were measured and their clinical significance. What this does tell us is that the adolescent brain appears more vulnerable than we might have assumed, which should inform our conversations with families about use patterns.” Clinical Perspective 💭 This study adds to growing evidence that [adolescent cannabis exposure](https://cedclinic.com/cannabis-impairment-testing-arizona-marijuana-dui-laws/) carries neurodevelopmental risks even at relatively low frequencies, challenging assumptions that occasional use is consequence-free during a critical period of brain maturation. However, clinicians should note important limitations when applying these findings: the study’s cross-sectional or observational design cannot establish causation, residual confounding from concurrent [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) or underlying mental health conditions remains difficult to exclude, and individual vulnerability likely varies based on genetics, timing of exposure, and product potency (which the study may not fully capture). Additionally, the gap between statistical significance and clinical meaningfulness warrants careful interpretation, as neuroimaging changes do not always translate to observable functional impairment. When counseling adolescents and families, this evidence supports a harm-reduction message that even infrequent cannabis use is not risk-free during adolescence, but practitioners should combine this research with individualized assessment of each teen’s use patterns 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Study%20Published%20in%20Pediatrics%20Finds%20Infrequent%20Cannabis%20Use%20Can%20Impact%20Adolescent%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71393)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71393)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Study%20Published%20in%20Pediatrics%20Finds%20Infrequent%20Cannabis%20Use%20Can%20Impact%20Adolescent%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71393)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Rising Substance Use Among Gen Z in Their Early Twenties](https://cedclinic.com/substance-use-trends-gen-z-early-twenties/) - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) 📰 Source: [https://x.com/heather_berlin/status/2080749905786581495](https://x.com/heather_berlin/status/2080749905786581495) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).